Company: ENTXW
Filing Date: 2025-05-14
Form Type: PRE 14A
Source: 0001178913-25-001794
Chunk: 65

Company: Entera Bio Ltd.
Filing Date: 2025-05-14
Form: PRE 14A
Chunk 65
---
 Burshtein will be entitled to receive a one-time grant of 26,316 RSUs (the “2025 RSUs”) in lieu of a cash bonus for 2024 under the 2018 Plan, and subject to the requirements of applicable laws and regulations. The 2025 RSUs shall vest as follows: provided that Dr. Burshtein has not undergone a Termination of Service (as defined in the 2018 Plan) prior to the applicable vesting date, the 2025 RSUs shall vest over a one (1) year period, with 100% of the 2025 RSUs vesting in four substantially equal portions over the 12 month period following April 28, 2025, on a quarterly basis, rounded down to the nearest whole share, provided, that with respect to the last such quarterly installment, the number of 2025 RSUs that vest in the installment shall be such that Dr. Burshtein will be fully vested in the total number of 2025 RSUs listed above as of such applicable quarterly anniversary (i.e., such that one hundred percent (100%) of the 2025 RSUs shall become fully vested on April 28, 2026). |

| (iii) | 2025 Salary Increase. Dr. Burshtein will be entitled to an annual gross base salary of $200,000 (the “Updated Salary”), effective as of April 1, 2025, in accordance with the Company’s regular payroll practice in effect from time to time. For the avoidance of doubt, all other terms and social benefits under his employment agreement affected by a base salary shall be updated in accordance with the Updated Salary effective as of April 1, 2025. |

38 Proposal Shareholders are being asked to adopt the following resolution: “RESOLVED, that the revised compensation terms to Gregory Burshtein, our Chief of Research & Development, as described in Proposal Three of the Company’s Proxy Statement for the Company’s 2025 Annual Meeting, be, and are hereby, ratified and approved.” Vote Required Proposal Three requires the affirmative vote of a simple majority of our Ordinary Shares voted in person or by proxy, meaning that more votes must be cast “for” than “against” for Proposal Three, and abstentions and broker non-votes have no effect on the outcome of Proposal Three. In addition to the simple majority vote described above, the Israeli Companies Law requires further, to the extent applicable pursuant to the provisions